Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (386)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06101758 | Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study(SARCOLIVER) | unknown | N/A | 125 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06088459 | NWRD06 DNA Plasmid for HCC After Radical Resection | unknown | Phase 1 | 9 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070623 | Follow up After TACE by Elastography and Color Doppler. | unknown | — | 54 | Assiut UniversityOTHER | 0 | Oct 6, 2023 | clinicaltrials |
| NCT06042842 | The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC | unknown | — | 102 | Assiut UniversityOTHER | 0 | Oct 4, 2023 | clinicaltrials |
| NCT06062706 | Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy | unknown | — | 3,448 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05352646 | NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 1 | 26 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05010434 | Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039280 | Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization. | unknown | N/A | 150 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05992584 | Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06001567 | Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03447951 | A Study of PTS100 in Primary HCC Patients(OASES) | unknown | Phase 2 | 33 | Gongwin Biopharm Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05371873 | A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer | unknown | — | 250 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05448222 | Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies | unknown | — | 300 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06034977 | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06031480 | Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors(FAITH) | unknown | Phase 2 | 55 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06029829 | The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. | unknown | Phase 2 | 60 | Xin-Hua XuOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06023147 | A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) | unknown | N/A | 298 | Xuhua DuanOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04852211 | Laparoscopic Versus Open Major Hepatectomy for HCC Hepatectomy for Hepatocellular Carcinoma(AP-LAPO) | unknown | N/A | 212 | Chinese University of Hong KongOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05681949 | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards(ADBoard) | unknown | N/A | 1,200 | Charite University, Berlin, GermanyOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03731923 | Abbreviated MRI for HCC Surveillance | unknown | N/A | 257 | Seoul National University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04135690 | HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05987514 | Multimodal Ultrasound and Hepatocellular Response to Local Treatments | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05981066 | A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 48 | Peking Union Medical College HospitalOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05970159 | Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery(REAL) | unknown | — | 480 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04680598 | Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study | unknown | — | 800 | Sun Yat-sen UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05971199 | Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 27 | Zhejiang Cancer HospitalOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05967429 | Predictors of Sorafenib Response in HCC | unknown | — | 80 | Sohag UniversityOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05957640 | Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 40 | Zhongda HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05576909 | Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation | unknown | Phase 2 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05932719 | Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators(COLLAT-COVID) | unknown | — | 4,000 | Hospices Civils de LyonOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04445532 | Hepatobiliary Tumors Tissue Samples Acquisition | unknown | — | 450 | Peking Union Medical College HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05925413 | Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 41 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04512833 | CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis | unknown | — | 60 | Beijing 302 HospitalOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05897268 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)(CASTLE-10) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05263219 | DEB-TACE+HAIC vs. HAIC for Large HCC | unknown | Phase 3 | 230 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913583 | Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection | unknown | — | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05908916 | Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 51 | Yonsei UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05903456 | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05889949 | Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | unknown | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Jun 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 15, 2023source: clinicaltrials